The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China

作者：Jiujie Cui, Qihan Fu, Xiaobing Chen, Yanling Wang, Qi Li, Feng Wang, Zhihua Li, Guanghai Dai, Yusheng Wang, Hongmei Zhang, Houjie Liang, Jun Zhou, Liu Yang, Feng‐Hua Wang, Leizhen Zheng, Xiaofeng Chen, Ping Gong, Jiang Liu, Ying Yuan, Lin Wang, Yuejuan Cheng, Jun Zhang, Yuhong Zhou, Weijian Guo, Xianbao Zhan, Zhengyun Zou, Da Li, Shan Zeng, Enxiao Li, Zhiwei Li, Zan Teng, Dan Cao, Jie Kan, Jianping Xiong, Ming Quan, Jiayu Yao, Haiyan Yang, Liwei Wang · 发表于：Journal of Pancreatology · 年份：2023 · DOI：10.1097/jp9.0000000000000155 · 被引用次数：14 · 研究领域：Pancreatic and Hepatic Oncology Research、Renal cell carcinoma treatment、Cancer Research and Treatments

Objective: Real-world diagnostic and treatment data for pancreatic cancer in China are lacking. As such, the present study investigated the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer (including locally advanced and metastatic disease) in the Hospital-based Advanced Pancreatic Cancer Cohort in China of the China Pancreas Data Center database. Methods: A total of 5349 Chinese patients with advanced pancreatic cancer were identified from a database. The entire course of real-world pancreatic cancer management was analyzed. Results: The proportion of patients with advanced pancreatic cancer was higher among males than females (62.4% vs 37.6%, respectively). Patients typically had a history of hypertension (30.8%), diabetes (21.6%), and cholangitis (20.2%). Abdominal pain (51.6%), abdominal distension (27.1%), jaundice (20.1%), and weight loss (16.3%) were the main symptoms observed in patients with advanced pancreatic cancer in this cohort. Serum carbohydrate antigen (CA)19-9 is one of the most common tumor markers. In the present study, 2562 patients underwent first-line therapy. The median progression-free survival (PFS) for patients undergoing first-line therapy was 4.1 months. The major options for first-line therapy included gemcitabine (GEM) plus S-1 (GS/X) (23.4%), nab-paclitaxel plus GEM (AG) (18.1%), oxaliplatin, irinotecan, and leucovorin-modulated fluorouracil (FOLFIRINOX; 11.9%), nab-paclitaxel plus S-1 (AS) (8.9%), and GEM combin...